Aurobindo Pharma (NSE:AUROPHARMA, BOM:524804) reported a slight decline in its consolidated attributable net profit to 9.03 billion Indian rupees in the fiscal fourth quarter ended March 31, against 9.09 billion rupees a year ago.
Earnings per share inched up to 15.56 rupees compared with the year-ago figure of 15.51 rupees, according to a Monday filing to the Indian stock exchanges by the pharmaceutical manufacturer.
Revenue from operations in fiscal Q4 increased to 83.8 billion rupees from 75.8 billion rupees a year earlier.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.